• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

乐伐替尼对具有成纤维细胞生长因子受体 4 表达的肝细胞癌的疗效：病例报告及文献复习。

Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature.

机构信息

Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.

出版信息

Intern Med. 2021 Jun 1;60(11):1709-1715. doi: 10.2169/internalmedicine.6580-20. Epub 2020 Dec 29.

DOI:10.2169/internalmedicine.6580-20
PMID:33390501
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8222122/
Abstract

Basic and clinical research have shown that the expression of molecules involved in the hepatocellular carcinoma (HCC) cell signaling pathway is related to the sensitivity to molecular-targeted agents. We herein report a case of HCC that was effectively treated with lenvatinib after a poor response to sorafenib. The tumor showed a high expression of fibroblast growth factor receptor 4, which is reportedly related to the sensitivity to lenvatinib in vitro. The information obtained from this case and from our literature review highlights the importance of assessing the expression of the molecules involved in tumors for effective precision medicine.

摘要

基础和临床研究表明，参与肝细胞癌（HCC）细胞信号通路的分子的表达与对分子靶向药物的敏感性相关。我们在此报告一例 HCC 病例，该病例在索拉非尼治疗反应不佳后，用仑伐替尼治疗取得了良好的效果。该肿瘤表现出高表达的成纤维细胞生长因子受体 4，据报道，这与仑伐替尼在体外的敏感性有关。从该病例和我们的文献复习中获得的信息强调了评估肿瘤中相关分子表达对于有效精准医学的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96fb/8222122/05aaff3fb1ad/1349-7235-60-1709-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96fb/8222122/0659fb302773/1349-7235-60-1709-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96fb/8222122/2cdce32abed4/1349-7235-60-1709-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96fb/8222122/9afb932e213b/1349-7235-60-1709-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96fb/8222122/05aaff3fb1ad/1349-7235-60-1709-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96fb/8222122/0659fb302773/1349-7235-60-1709-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96fb/8222122/2cdce32abed4/1349-7235-60-1709-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96fb/8222122/9afb932e213b/1349-7235-60-1709-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96fb/8222122/05aaff3fb1ad/1349-7235-60-1709-g004.jpg

相似文献

1
Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature.乐伐替尼对具有成纤维细胞生长因子受体 4 表达的肝细胞癌的疗效：病例报告及文献复习。
Intern Med. 2021 Jun 1;60(11):1709-1715. doi: 10.2169/internalmedicine.6580-20. Epub 2020 Dec 29.
2
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.仑伐替尼通过抑制 FGFR1-3 信号通路而非 FGFR4 信号通路抑制 HCC 中的癌症干细胞样细胞。
Carcinogenesis. 2021 Feb 11;42(1):58-69. doi: 10.1093/carcin/bgaa049.
3
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.成纤维细胞生长因子 19/成纤维细胞生长因子受体 4 信号抑制对多激酶抑制剂在肝细胞癌中抗肿瘤活性的影响。
Sci Rep. 2021 Mar 5;11(1):5303. doi: 10.1038/s41598-021-84117-9.
4
Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.仑伐替尼通过抑制 FGFR-MAPK 级联反应诱导激活 FGF 信号通路的人肝癌细胞死亡。
Biochem Biophys Res Commun. 2019 May 21;513(1):1-7. doi: 10.1016/j.bbrc.2019.02.015. Epub 2019 Mar 31.
5
ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.ST6GAL1 是仑伐替尼敏感的 FGF19 驱动型肝细胞癌的新型血清生物标志物。
Clin Cancer Res. 2021 Feb 15;27(4):1150-1161. doi: 10.1158/1078-0432.CCR-20-3382. Epub 2020 Dec 7.
6
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.乐伐替尼靶向成纤维细胞生长因子受体4以增强抗程序性细胞死亡蛋白1在肝癌中的抗肿瘤免疫反应。
Hepatology. 2021 Nov;74(5):2544-2560. doi: 10.1002/hep.31921. Epub 2021 Aug 25.
7
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.成纤维细胞生长因子19/成纤维细胞生长因子受体4信号通路导致肝细胞癌对索拉非尼产生耐药性。
J Exp Clin Cancer Res. 2017 Jan 9;36(1):8. doi: 10.1186/s13046-016-0478-9.
8
Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.成纤维细胞生长因子 19 对索拉非尼介导的肝癌细胞一氧化氮产生的影响——一份简短报告。
Cell Oncol (Dordr). 2018 Feb;41(1):85-91. doi: 10.1007/s13402-017-0354-4. Epub 2017 Oct 5.
9
Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines and .仑伐替尼对人肝癌细胞系和 的抗增殖作用。
Anticancer Res. 2019 Nov;39(11):5973-5982. doi: 10.21873/anticanres.13802.
10
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.仑伐替尼的免疫调节活性有助于 Hepa1-6 肝癌模型的抗肿瘤活性。
Cancer Sci. 2018 Dec;109(12):3993-4002. doi: 10.1111/cas.13806. Epub 2018 Nov 16.

引用本文的文献

1
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.乐伐替尼与免疫检查点抑制剂在肝细胞癌中的应用：作用机制、临床疗效及未来展望
J Hematol Oncol. 2024 Dec 21;17(1):130. doi: 10.1186/s13045-024-01647-1.
2
Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).乐伐替尼在晚期肝细胞癌中的临床应用作用及其耐药机制（综述）
Am J Cancer Res. 2024 Sep 15;14(9):4113-4171. doi: 10.62347/UJVP4361. eCollection 2024.
3
DEP domain containing 1B (DEPDC1B) exerts the tumor promoter in hepatocellular carcinoma through activating p53 signaling pathway via kinesin family member 23 (KIF23).

本文引用的文献

1
Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.肿瘤成纤维细胞生长因子受体4水平可预测晚期肝细胞癌患者使用乐伐替尼的疗效。
Clin Transl Gastroenterol. 2020 May;11(5):e00179. doi: 10.14309/ctg.0000000000000179.
2
Gene Therapy for Liver Cancers: Current Status from Basic to Clinics.肝癌的基因治疗：从基础到临床的现状
Cancers (Basel). 2019 Nov 25;11(12):1865. doi: 10.3390/cancers11121865.
3
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
DEP 结构域包含 1B（DEPDC1B）通过激活驱动蛋白家族成员 23（KIF23）的 p53 信号通路在肝细胞癌中发挥肿瘤促进作用。
Bioengineered. 2022 Jan;13(1):1103-1114. doi: 10.1080/21655979.2021.2017629.
BLU-554 单药治疗肝细胞癌的首次人体 I 期临床试验结果：异常 FGF19 信号通路激活可作为驱动事件
Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1.
4
A global view of hepatocellular carcinoma: trends, risk, prevention and management.全球视角下的肝细胞癌：趋势、风险、预防与管理。
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
5
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.乐伐替尼用于超出七项标准且肝功能为Child-Pugh A级的中期肝细胞癌患者的初始治疗：一项概念验证研究。
Cancers (Basel). 2019 Jul 31;11(8):1084. doi: 10.3390/cancers11081084.
6
Molecular and histological correlations in liver cancer.肝癌的分子和组织学相关性。
J Hepatol. 2019 Sep;71(3):616-630. doi: 10.1016/j.jhep.2019.06.001. Epub 2019 Jun 10.
7
Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review.慢性乙型和丙型肝炎感染中促使肝硬化向肝细胞癌进展的分子机制：综述。
Int J Mol Sci. 2019 Mar 18;20(6):1358. doi: 10.3390/ijms20061358.
8
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.肝细胞癌的全身治疗：最新进展
Cancers (Basel). 2018 Oct 30;10(11):412. doi: 10.3390/cancers10110412.
9
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
10
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.仑伐替尼抑制人肝癌模型中的血管生成和肿瘤成纤维细胞生长因子信号通路。
Cancer Med. 2018 Jun;7(6):2641-2653. doi: 10.1002/cam4.1517. Epub 2018 May 7.